RNA vaccines train the immune system in a similar way to traditional vaccines, but they use a different strategy to get there ...

Morgan Stanley lowered the firm’s price target on Moderna (MRNA) to $32 from $39 and keeps an Equal Weight rating on the shares. The firm ...

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

We recently published a list of Jim Cramer Says Wait A Little & Discusses These 11 Stocks. In this article, we are going to ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Learn more about whether Ionis Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Moderna, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

However, in the later stages of the pandemic, demand for the product declined, and Moderna shifted to a loss. For example, ...

Vaccine stocks have been under significant pressure since the FDA's top vaccine official resigned. Seeking Alpha analysts ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...